Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?

References

• Abbas UL, Anderson RM, Mellors JW. 2007. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PloS One. 2:e875.
   PubMed Web of Science ®Google Scholar
• Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. 2012. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 4:151ra25.
   Web of Science ®Google Scholar
• Attia S, Egger M, Muller M, Zwahlen M, Low N. 2009. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 23:1397–1404.
   PubMed Web of Science ®Google Scholar
• Azcoaga-Lorenzo A, Ferreyra C, Alvarez A, Palma PP, Velilla E, del Amo J. 2011. Effectiveness of a PMTCT programme in rural Western Kenya. AIDS Care. 23:274–280.
   PubMed Web of Science ®Google Scholar
• Baden LR, Dolin R. 2012. The road to an effective HIV vaccine. N Engl J Med. 366:1343–1344.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al.; Partners PrEP Study Team. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 367:399–410.
   PubMed Web of Science ®Google Scholar
• Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. 2007. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 369:643–656.
   PubMed Web of Science ®Google Scholar
• Baird JK, Fryauff DJ, Hoffman SL. 2003. Primaquine for prevention of malaria in travelers. Clin Infect Dis. 37:1659–1667.
   PubMed Web of Science ®Google Scholar
• Bartholow BN, MacQueen KM, Douglas JM Jr, Buchbinder S, McKirnan D, Judson FN. 1997. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol. 16:108–115.
   PubMedGoogle Scholar
• Bartlett JG, Anderson JR. 2000. Public health service task force updates recommendations for use of antiretroviral drugs in pregnant women. Hopkins HIV Rep. 12:8–9, 11–2.
   PubMedGoogle Scholar
• Blanchard JF, O’Neil J, Ramesh B, Bhattacharjee P, Orchard T, Moses S. 2005. Understanding the social and cultural contexts of female sex workers in Karnataka, India: implications for prevention of HIV infection. J Infect Dis. 191:S139–S46.
   PubMed Web of Science ®Google Scholar
• Boberg EW, Gustafson DH, Hawkins RP, Chan CL, Bricker E, Pingree S, Berhe H. 1995. Development, acceptance, and use patterns of a computer-based education and social support system for people living with AIDS/HIV infection. Comput Human Behav. 11:289–311.
   Web of Science ®Google Scholar
• Burki TK. 2011. Discrimination against people with HIV persists in China. Lancet. 377:286–287.
   PubMed Web of Science ®Google Scholar
• Campbell C, Foulis CA, Maimane S, Sibiya Z. 2005. “I have an evil child at my house”: stigma and HIV/AIDS management in a South African community. Am J Public Health. 95:808–815.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Herbst JH, Koppenhaver RT, Smith DK. 2013. Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. Am J Prev Med. 44:S63–S69.
   PubMedGoogle Scholar
• Cao X, Sullivan SG, Xu J, Wu Z. 2006. Understanding HIV-related stigma and discrimination in a “blameless” population. AIDS Educ Prev. 18:518–528.
   PubMed Web of Science ®Google Scholar
• Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. 1997. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 337:1485–1490.
   PubMed Web of Science ®Google Scholar
• Cassell MM, Halperin DT, Shelton JD, Stanton D. 2006. Risk compensation: the Achilles’ heel of innovations in HIV prevention? BMJ. 332:605–607.
   PubMed Web of Science ®Google Scholar
• Chesney MA, Chambers DB, Kahn JO. 1997. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 16:266–271.
   PubMedGoogle Scholar
• Chesney MA. 2000. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 30:S171–S176.
   PubMed Web of Science ®Google Scholar
• Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. 2013. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 381:2083–2090.
   PubMed Web of Science ®Google Scholar
• Clavel F, Hance AJ. 2004. HIV drug resistance. N Engl J Med.350: 1023–1035.
   PubMed Web of Science ®Google Scholar
• Coughlin SS. 2006. Ethical issues in epidemiologic research and public health practice. Emerg Themes Epidemiol. 3:16.
   PubMedGoogle Scholar
• Crepaz N, Hart TA, Marks G. 2004. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA. 292:224–236.
   PubMed Web of Science ®Google Scholar
• Crosby RA, Holtgrave DR. 2006. Will sexual risk behaviour increase after being vaccinated for AIDS? Int J Std AIDS. 17:180–184.
   PubMed Web of Science ®Google Scholar
• Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, et al. 2008. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5:e16.
   PubMed Web of Science ®Google Scholar
• Doherty T, Besser M, Donohue S, Kamoga N, Stoops N, Williamson L, Visser R. 2003. An evaluation of the Prevention of Mother-to-Child Transmission (PMTCT) of HIV Initiative in South Africa: Lessons and Key Recommendations. Durban: Health Systems Trust.
   Google Scholar
• Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. 2001. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS. 15:369–378.
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 191:654–665.
   PubMed Web of Science ®Google Scholar
• Fonner VA, Denison J, Kennedy CE, O’Reilly K, Sweat M. 2012. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. Cochrane Database Syst Rev. 9:CD001224.
   Google Scholar
• Galea J, Kinsler J, Salazar X, Lee SJ, Giron M, Sayles JN, et al. 2011. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J Std AIDS. 22:256–262.
   PubMed Web of Science ®Google Scholar
• García OP, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. 2002. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 30:105–110.
   PubMed Web of Science ®Google Scholar
• Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, et al. 2010. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2:14ra4.
   PubMed Web of Science ®Google Scholar
• Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, et al. 2008. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 5:e28.
   PubMed Web of Science ®Google Scholar
• Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y. 2006. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 368:505–510.
   PubMed Web of Science ®Google Scholar
• Gordillo V, del Amo J, Soriano V, González-Lahoz J. 1999. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 13:1763–1769.
   PubMed Web of Science ®Google Scholar
• Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, Jaoko WG, et al. 2007. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS. 21:501–507.
   PubMed Web of Science ®Google Scholar
• Grant RM, Buchbinder S, Cates W Jr, Clarke E, Coates T, Cohen MS, et al. 2005. AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science. 309:2170–2171.
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al.; iPrEx Study Team. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 363:2587–2599.
   PubMed Web of Science ®Google Scholar
• Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. 2007. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 369:657–666.
   PubMed Web of Science ®Google Scholar
• Halperin DT. 1999. Heterosexual anal intercourse: prevalence, cultural factors, and HIV infection and other health risks, Part I. AIDS Patient Care STDs. 13:717–730.
   PubMed Web of Science ®Google Scholar
• Hammond E, Nolan D, McKinnon E, Pace C, Matcalf C, Mallal S. 2005. Assessing the contribution of ART, HIV and host factors to adipose tissue changes occurring in HIV-infected individuals: risk profile for lipoatrophy. Antivir Ther. 10:L4.
   Web of Science ®Google Scholar
• Hart GJ, Williamson LM. 2005. Increase in HIV sexual risk behaviour in homosexual men in Scotland, 1996–2002: prevention failure? Sex Transm Infect. 81:367–372.
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. 2013. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 8:e55013.
   PubMed Web of Science ®Google Scholar
• Heneine W, Kashuba A. 2012. HIV prevention by oral preexposure prophylaxis. Cold Spring Harb Perspect Med. 2:a007419.
   PubMed Web of Science ®Google Scholar
• Hofer CB, Harrison LH, Struchiner CJ, Moreira RI, do Lago RF, de Melo MF, Schechter M. 2000. Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. Projecto Praca Onze Study Group. J Acquir Immune Defic Syndr. 25:188–191.
   PubMed Web of Science ®Google Scholar
• Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS. 2009. Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database Syst Rev. CD006734. doi: https://doi.org/10.1002/14651858.
   Google Scholar
• Jones F, Harris P, Waller H, Coggins A. 2005. Adherence to an exercise prescription scheme: The role of expectations, self-efficacy, stage of change and psychological well-being. Br J Health Psychol. 10:359–378.
   PubMed Web of Science ®Google Scholar
• Kalichman SC. 1998. Post-exposure prophylaxis for HIV infection in gay and bisexual men. Implications for the future of HIV prevention. Am J Prev Med. 15:120–127.
   PubMed Web of Science ®Google Scholar
• Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al.; CAPRISA 004 Trial Group. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 329:1168–1174.
   PubMed Web of Science ®Google Scholar
• Kim SC, Becker S, Dieffenbach C, Hanewall BS, Hankins C, Lo YR, et al. 2010. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc. 13:24.
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. 1997. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis. 175:1051–1055.
   PubMed Web of Science ®Google Scholar
• Li L, Lee SJ, Thammawijaya P, Jiraphongsa C, Rotheram-Borus MJ. 2009. Stigma, social support, and depression among people living with HIV in Thailand. AIDS Care. 21:1007–1013.
   PubMed Web of Science ®Google Scholar
• Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. 2006. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 166:49–56.
   PubMed Web of Science ®Google Scholar
• Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, Matheson T, et al. 2008. Limited knowledge and use of HIV post-and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 47:241–247.
   PubMed Web of Science ®Google Scholar
• Maman S, Abler L, Parker L, Lane T, Chirowodza A, Ntogwisangu J, et al. 2009. A comparison of HIV stigma and discrimination in five international sites: the influence of care and treatment resources in high prevalence settings Soc Sci Med. 68:2271–2278.
   PubMed Web of Science ®Google Scholar
• Martin JN, Roland ME, Neilands TB, Krone MR, Bamberger JD, Kohn RP, et al. 2004. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS. 18:787–792.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Hall W. 1997. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. London: Martin Dunitz.
   Google Scholar
• McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. 2011. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 203:1791–1801.
   PubMed Web of Science ®Google Scholar
• Michaels SH, Clark R, Kissinger P. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 339:405–406.
   PubMed Web of Science ®Google Scholar
• Mondou E, Sorbel J, Anderson J, Mommeja-Marin H, Rigney A, Rousseau F. 2005. Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine. Clin Infect Dis. 41:e45–e47.
   PubMed Web of Science ®Google Scholar
• Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. 2010. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 376:532–539.
   PubMed Web of Science ®Google Scholar
• Na H, Detels R. 2005. The HIV epidemic in China: history, response, and challenge. Cell Res. 15:825–832.
   PubMed Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. 2005. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 293:817–829.
   PubMed Web of Science ®Google Scholar
• Nodin DN, Carballo-Dieguez A, Ventuneac AM, Balan IC, Remien R. 2008. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care. 20:106–115.
   PubMed Web of Science ®Google Scholar
• Ostrow DE, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, Vanable PA, et al. 2002. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS. 16:775–780.
   PubMed Web of Science ®Google Scholar
• Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. 2009. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 48:806–815.
   PubMed Web of Science ®Google Scholar
• Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, et al. 2009. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol. 83.
   PubMed Web of Science ®Google Scholar
• Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. 2011. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 3:112re4.
   PubMed Web of Science ®Google Scholar
• Peretti-Watel P, Spire B, Pierret J, Lert F, Obadia Y, Group TV. 2006. Management of HIV-related stigma and adherence to HAART: evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA 2003). AIDS Care. 18:254–261.
   PubMed Web of Science ®Google Scholar
• Pinkerton SD, Abramson PR. 1997. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med. 44:1303–1312.
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 194:1661–1671.
   PubMed Web of Science ®Google Scholar
• Pretorius C, Stover J, Bollinger L, Bacaër N, Williams B. 2010. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PloS One. 5:e13646.
   PubMedGoogle Scholar
• Ramjee G, Govinden R, Morar NS, Mbewu A. 2007. South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Med. 4:e235.
   PubMed Web of Science ®Google Scholar
• Ray M, Logan R, Sterne J, Hernández-Díaz S, Robins JM, et al.; HIV-CAUSAL Collaboration. 2010. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 24:123–137.
   PubMed Web of Science ®Google Scholar
• Rueda S, Park-Wyllie LY, Bayoumi A, Tynan AM, Antoniou TA, Rourke SB, Glazier RH. 2006. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev.CD001442.
   PubMedGoogle Scholar
• Rutenberg N, Kalibala S, Baek C, Rosen J. 2003. Evaluation of United Nations-Supported Pilot Projects for the Prevention of Mother-to-Child Transmission of HIV: Overview of Findings. New York: UNICEF.
   Google Scholar
• Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH. 2004. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 35:519–525.
   PubMed Web of Science ®Google Scholar
• Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. 2003. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 37:1112–1118.
   PubMed Web of Science ®Google Scholar
• Shao Y. 2006. AIDS epidemic at age 25 and control efforts in China. Retrovirology. 3:87.
   PubMed Web of Science ®Google Scholar
• Singh JA, Mills EJ. 2005. The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med. 2:e234.
   PubMed Web of Science ®Google Scholar
• Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, et al. 2005. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 54:1–20.
   PubMedGoogle Scholar
• Smith SM. 2004. Pre-exposure chemoprophylaxis for HIV: it is time. Retrovirology. 1:16.
   PubMedGoogle Scholar
• Stirratt MJ, Gordon CM. 2008. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 5:186–192.
   PubMedGoogle Scholar
• Stolte IG, de Wit JB, van Eeden A, Coutinho RA, Dukers NH. 2004. Perceived viral load, but not actual HIV-1-RNA load, is associated with sexual risk behaviour among HIV-infected homosexual men. AIDS. 18:1943–1949.
   PubMed Web of Science ®Google Scholar
• Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, Monsour M, et al. 2006. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis. 194:904–911.
   PubMed Web of Science ®Google Scholar
• Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. 2002. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr. 29:207–220.
   PubMed Web of Science ®Google Scholar
• Templeton DJ, Millett GA, Grulich AE. 2010. Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men. Curr Opin Infect Dis. 23:45–52.
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. 2012. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 367:423–434.
   PubMed Web of Science ®Google Scholar
• Trial and failure. Only the most promising AIDS gels should reach large-scale trials. 2007. Nature. 446:1. doi: https://doi.org/10.1038/446001a [published Online First:Epub Date]
   Google Scholar
• Tsai CC, Emau P, Sun JC, Beck TW, Tran CA, Follis KE, et al. 2000. Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J Med Primatol. 29:248–258.
   PubMed Web of Science ®Google Scholar
• Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH. 2010. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep. 7:210–219.
   PubMedGoogle Scholar
• Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K. 2010. Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice. J Acquir Immune Defic Syndr. 55:8–13.
   PubMed Web of Science ®Google Scholar
• Valdiserri RO. 2002. HIV/AIDS stigma: an impediment to public health. Am J Public Health. 92:341–342.
   PubMed Web of Science ®Google Scholar
• van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. 2004. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 40:1421–1425.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. 2012. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 367:411–422.
   PubMed Web of Science ®Google Scholar
• van der Straten A, Gómez CA, Saul J, Quan J, Padian N. 2000. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of post-exposure prevention and viral suppressive therapy. AIDS. 14:F47–F54.
   PubMed Web of Science ®Google Scholar
• Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. 2008. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One. 3:e2077.
   PubMed Web of Science ®Google Scholar
• Wagner G, Miller LG. 2004. Is the influence of social desirability on patients’ self-reported adherence overrated? J Acquir Immune Defic Syndr. 35:203–204.
   PubMed Web of Science ®Google Scholar
• Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. 2010. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.- 2006. AIDS. 24:1203–1212.
   PubMed Web of Science ®Google Scholar
• Wilde GJS. 1994. Target Risk: Dealing with the Danger of Death, Disease and Damage in Everyday Decisions. Toronto: PDE publications.
   Google Scholar
• Wu Z, Sun X, Sullivan SG, Detels R. 2006. HIV testing in China. Science. 312:1475–1476.
   PubMed Web of Science ®Google Scholar
• Youle M, Wainberg MA. 2003. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS. 17:937–938.
   PubMed Web of Science ®Google Scholar